| Somatic mutations of calreticulin in myeloproliferative neoplasms T Klampfl, H Gisslinger, AS Harutyunyan, H Nivarthi, E Rumi, JD Milosevic, ... New England Journal of Medicine 369 (25), 2379-2390, 2013 | 2381 | 2013 |
| Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants I Chachoua, C Pecquet, M El-Khoury, H Nivarthi, RI Albu, C Marty, ... Blood, The Journal of the American Society of Hematology 127 (10), 1325-1335, 2016 | 363 | 2016 |
| Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms JD Milosevic Feenstra, H Nivarthi, H Gisslinger, E Leroy, E Rumi, ... Blood, The Journal of the American Society of Hematology 127 (3), 325-332, 2016 | 309 | 2016 |
| Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis C Marty, C Pecquet, H Nivarthi, M El-Khoury, I Chachoua, M Tulliez, ... Blood, The Journal of the American Society of Hematology 127 (10), 1317-1324, 2016 | 289 | 2016 |
| Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer D Unterleuthner, P Neuhold, K Schwarz, L Janker, B Neuditschko, ... Angiogenesis 23, 159-177, 2020 | 211 | 2020 |
| Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis B Grabner, D Schramek, KM Mueller, HP Moll, J Svinka, T Hoffmann, ... Nature communications 6 (1), 6285, 2015 | 158 | 2015 |
| IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction C Rupp, M Scherzer, A Rudisch, C Unger, C Haslinger, N Schweifer, ... Oncogene 34 (7), 815-825, 2015 | 143 | 2015 |
| Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression N Kramer, J Schmöllerl, C Unger, H Nivarthi, A Rudisch, D Unterleuthner, ... Oncogene 36 (39), 5460-5472, 2017 | 125 | 2017 |
| STAT5BN642H is a driver mutation for T cell neoplasia HTT Pham, B Maurer, M Prchal-Murphy, R Grausenburger, ... The Journal of clinical investigation 128 (1), 387-401, 2018 | 92 | 2018 |
| Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants C Pecquet, I Chachoua, A Roy, T Balligand, G Vertenoeil, E Leroy, ... Blood, The Journal of the American Society of Hematology 133 (25), 2669-2681, 2019 | 91 | 2019 |
| Thrombopoietin receptor is required for the oncogenic function of CALR mutants H Nivarthi, D Chen, C Cleary, B Kubesova, R Jäger, E Bogner, C Marty, ... Leukemia 30 (8), 1759-1763, 2016 | 72 | 2016 |
| Activated STAT5 confers resistance to intestinal injury by increasing intestinal stem cell proliferation and regeneration S Gilbert, H Nivarthi, CN Mayhew, YH Lo, TK Noah, J Vallance, T Rülicke, ... Stem cell reports 4 (2), 209-225, 2015 | 71 | 2015 |
| Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin T Balligand, Y Achouri, C Pecquet, I Chachoua, H Nivarthi, C Marty, ... Leukemia 30 (8), 1775-1778, 2016 | 53 | 2016 |
| High activation of STAT5A drives peripheral T-cell lymphoma and leukemia B Maurer, H Nivarthi, B Wingelhofer, HTT Pham, M Schlederer, T Suske, ... Haematologica 105 (2), 435, 2020 | 45 | 2020 |
| The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth H Nivarthi, C Gordziel, M Themanns, N Kramer, M Eberl, B Rabe, ... Oncotarget 7 (32), 51096, 2016 | 40 | 2016 |
| A novel germline JAK2 mutation in familial myeloproliferative neoplasms E Rumi, AS Harutyunyan, I Casetti, D Pietra, H Nivarthi, R Moriggl, ... American journal of hematology 89 (1), 117-118, 2014 | 40 | 2014 |
| CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networks IZ Uras, B Maurer, H Nivarthi, P Jodl, K Kollmann, M Prchal-Murphy, ... Blood, The Journal of the American Society of Hematology 133 (15), 1677-1690, 2019 | 36 | 2019 |
| Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: perspectives for MPN therapy C Pecquet, T Balligand, I Chachoua, A Roy, G Vertenoeil, D Colau, ... Blood 132 (Supplement 1), 4-4, 2018 | 36 | 2018 |
| RETRACTED ARTICLE: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation T Javaheri, Z Kazemi, J Pencik, HTT Pham, M Kauer, R Noorizadeh, ... Cell death & disease 7 (10), e2419-e2419, 2016 | 25 | 2016 |
| Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms C Pecquet, N Papadopoulos, T Balligand, I Chachoua, A Tisserand, ... Blood 141 (8), 917-929, 2023 | 15 | 2023 |
